Clinical Trial Update: A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing safety and efficacy of lenvatinib as first-line treatment in unresectable hepatocellular carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Pharmaceuticals India Pvt. Ltd | Conditions: Carcinoma, Hepatocellular | Phase 4 | Status: COMPLETED